AR018139A1 - A N- [3-HIDROXI-5 [(1,4,5,6-TETRAHIDRO-5-HIDROXI-2-PYRIMIDINYL) AMINO] BENZOIL] GLICI-3- (3-HALO-5-HALO-2-HYDROXYPHENYL) COMPOUND ) -BALL ALANINE, COMPOSITION PHARMACEUTICAL AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT. - Google Patents
A N- [3-HIDROXI-5 [(1,4,5,6-TETRAHIDRO-5-HIDROXI-2-PYRIMIDINYL) AMINO] BENZOIL] GLICI-3- (3-HALO-5-HALO-2-HYDROXYPHENYL) COMPOUND ) -BALL ALANINE, COMPOSITION PHARMACEUTICAL AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT.Info
- Publication number
- AR018139A1 AR018139A1 ARP990100880A ARP990100880A AR018139A1 AR 018139 A1 AR018139 A1 AR 018139A1 AR P990100880 A ARP990100880 A AR P990100880A AR P990100880 A ARP990100880 A AR P990100880A AR 018139 A1 AR018139 A1 AR 018139A1
- Authority
- AR
- Argentina
- Prior art keywords
- hidroxi
- halo
- manufacture
- same
- glici
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Abstract
La presente invencion se refiere a compuestos de la formula (I) y a las sales aceptables para uso farmacéutico y a los isomeros de los mismos,donde X e Y son el mismo o diferente grupo halo. R es hidrogeno o alquilo C1-6. También se revela la composicion farmacéutica que lo contieney su uso en la fabricacion de medicamentos utiles para el tratamiento de afecciones mediadas por avbeta3 por inhibicion o antagonismo de lasintegrinas avbeta3.The present invention relates to compounds of the formula (I) and salts acceptable for pharmaceutical use and to the isomers thereof, where X and Y are the same or different halo group. R is hydrogen or C1-6 alkyl. It also reveals the pharmaceutical composition that contains it and its use in the manufacture of useful medicines for the treatment of conditions mediated by avbeta3 by inhibition or antagonism of lasintegrinas avbeta3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3427098A | 1998-03-04 | 1998-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR018139A1 true AR018139A1 (en) | 2001-10-31 |
Family
ID=21875345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990100880A AR018139A1 (en) | 1998-03-04 | 1999-03-02 | A N- [3-HIDROXI-5 [(1,4,5,6-TETRAHIDRO-5-HIDROXI-2-PYRIMIDINYL) AMINO] BENZOIL] GLICI-3- (3-HALO-5-HALO-2-HYDROXYPHENYL) COMPOUND ) -BALL ALANINE, COMPOSITION PHARMACEUTICAL AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT. |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP1060164A1 (en) |
JP (1) | JP2002505323A (en) |
KR (1) | KR20010041584A (en) |
CN (1) | CN1214011C (en) |
AP (1) | AP1244A (en) |
AR (1) | AR018139A1 (en) |
AU (1) | AU753230B2 (en) |
BG (1) | BG104740A (en) |
BR (1) | BR9908470A (en) |
CA (1) | CA2322207A1 (en) |
EA (1) | EA200000804A1 (en) |
EE (1) | EE200000506A (en) |
GE (1) | GEP20033118B (en) |
HR (1) | HRP20000574A2 (en) |
HU (1) | HUP0100865A3 (en) |
ID (1) | ID25591A (en) |
IL (1) | IL137653A0 (en) |
IS (1) | IS5582A (en) |
MY (1) | MY123908A (en) |
NO (1) | NO315703B1 (en) |
NZ (1) | NZ506598A (en) |
OA (1) | OA11530A (en) |
PL (1) | PL342726A1 (en) |
SK (1) | SK13002000A3 (en) |
TR (1) | TR200002542T2 (en) |
UA (1) | UA71906C2 (en) |
WO (1) | WO1999044994A1 (en) |
YU (1) | YU52000A (en) |
ZA (1) | ZA994406B (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
WO2001079173A2 (en) | 2000-04-17 | 2001-10-25 | Celltech R & D Limited | Enamine derivatives as cell adhesion molecules |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
US6921767B2 (en) * | 2000-06-15 | 2005-07-26 | Pharmacia Corporation | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives |
CA2417059A1 (en) | 2000-08-02 | 2002-02-07 | Celltech R&D Limited | 3-substituted isoquinolin-1-yl derivatives |
CA2510050A1 (en) * | 2002-12-20 | 2004-07-22 | Pharmacia Corporation | The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
KR20080031266A (en) * | 2005-06-10 | 2008-04-08 | 바이파 사이언스 인코포레이티드 | Parp modulators and treatment of cancer |
EP2131861A2 (en) | 2007-03-01 | 2009-12-16 | Mallinckrodt Inc. | Integrated photoactive small molecules and uses thereof |
JP4792124B1 (en) * | 2010-11-15 | 2011-10-12 | エフイートレード株式会社 | Method for molding protective film for vehicle and method for manufacturing protective film for vehicle |
US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
CN104640857B (en) | 2012-07-18 | 2017-07-04 | 圣路易斯大学 | As the beta amino acids derivative of integrin antagonists |
KR20160147007A (en) | 2014-05-30 | 2016-12-21 | 화이자 인코포레이티드 | Carbonitrile derivatives as selective androgen receptor modulators |
US9856201B2 (en) * | 2014-06-04 | 2018-01-02 | Monsanto Technology Llc | 3,6-dichlorosalicylic acid compounds and related synthetic processes |
SG11201805387RA (en) | 2015-12-30 | 2018-07-30 | Univ Saint Louis | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists |
MX2022014200A (en) | 2020-05-14 | 2022-12-07 | Ube Corp | 1, 4, 5, 6-tetrahydropyrimidine-2-amine derivative. |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
JPWO2023085396A1 (en) | 2021-11-12 | 2023-05-19 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE203234T1 (en) * | 1995-08-30 | 2001-08-15 | Searle & Co | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINOBENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS |
-
1999
- 1999-02-11 ZA ZA9904406A patent/ZA994406B/en unknown
- 1999-02-22 UA UA2000095148A patent/UA71906C2/en unknown
- 1999-02-22 EA EA200000804A patent/EA200000804A1/en unknown
- 1999-02-22 WO PCT/US1999/003281 patent/WO1999044994A1/en not_active Application Discontinuation
- 1999-02-22 PL PL99342726A patent/PL342726A1/en unknown
- 1999-02-22 YU YU52000A patent/YU52000A/en unknown
- 1999-02-22 AU AU32947/99A patent/AU753230B2/en not_active Ceased
- 1999-02-22 EP EP99937927A patent/EP1060164A1/en active Pending
- 1999-02-22 IL IL13765399A patent/IL137653A0/en unknown
- 1999-02-22 SK SK1300-2000A patent/SK13002000A3/en unknown
- 1999-02-22 NZ NZ506598A patent/NZ506598A/en unknown
- 1999-02-22 ID IDW20001695A patent/ID25591A/en unknown
- 1999-02-22 OA OA1200000238A patent/OA11530A/en unknown
- 1999-02-22 HU HU0100865A patent/HUP0100865A3/en unknown
- 1999-02-22 AP APAP/P/2000/001893A patent/AP1244A/en active
- 1999-02-22 KR KR1020007009774A patent/KR20010041584A/en not_active Application Discontinuation
- 1999-02-22 TR TR2000/02542T patent/TR200002542T2/en unknown
- 1999-02-22 CN CNB998035815A patent/CN1214011C/en not_active Expired - Fee Related
- 1999-02-22 EE EEP200000506A patent/EE200000506A/en unknown
- 1999-02-22 BR BR9908470-8A patent/BR9908470A/en not_active Application Discontinuation
- 1999-02-22 CA CA002322207A patent/CA2322207A1/en not_active Abandoned
- 1999-02-22 GE GEAP19995537A patent/GEP20033118B/en unknown
- 1999-02-22 JP JP2000534538A patent/JP2002505323A/en active Pending
- 1999-03-02 AR ARP990100880A patent/AR018139A1/en unknown
- 1999-03-03 MY MYPI99000772A patent/MY123908A/en unknown
-
2000
- 2000-08-04 IS IS5582A patent/IS5582A/en unknown
- 2000-08-30 NO NO20004316A patent/NO315703B1/en not_active IP Right Cessation
- 2000-09-01 HR HR20000574A patent/HRP20000574A2/en not_active Application Discontinuation
- 2000-09-01 BG BG104740A patent/BG104740A/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO20004316L (en) | 2000-11-06 |
WO1999044994A1 (en) | 1999-09-10 |
IS5582A (en) | 2000-08-04 |
MY123908A (en) | 2006-06-30 |
BR9908470A (en) | 2000-12-05 |
YU52000A (en) | 2003-02-28 |
EE200000506A (en) | 2002-04-15 |
CA2322207A1 (en) | 1999-09-10 |
IL137653A0 (en) | 2001-10-31 |
BG104740A (en) | 2001-02-28 |
AU3294799A (en) | 1999-09-20 |
HUP0100865A2 (en) | 2001-08-28 |
HUP0100865A3 (en) | 2001-11-28 |
ZA994406B (en) | 2000-02-11 |
JP2002505323A (en) | 2002-02-19 |
KR20010041584A (en) | 2001-05-25 |
AP1244A (en) | 2004-02-04 |
CN1214011C (en) | 2005-08-10 |
HRP20000574A2 (en) | 2001-08-31 |
PL342726A1 (en) | 2001-07-02 |
CN1291978A (en) | 2001-04-18 |
NO20004316D0 (en) | 2000-08-30 |
OA11530A (en) | 2004-05-17 |
ID25591A (en) | 2000-10-19 |
TR200002542T2 (en) | 2001-05-21 |
EP1060164A1 (en) | 2000-12-20 |
SK13002000A3 (en) | 2001-07-10 |
NO315703B1 (en) | 2003-10-13 |
GEP20033118B (en) | 2003-11-25 |
EA200000804A1 (en) | 2001-04-23 |
AP2000001893A0 (en) | 2000-09-30 |
NZ506598A (en) | 2003-07-25 |
UA71906C2 (en) | 2005-01-17 |
AU753230B2 (en) | 2002-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR018139A1 (en) | A N- [3-HIDROXI-5 [(1,4,5,6-TETRAHIDRO-5-HIDROXI-2-PYRIMIDINYL) AMINO] BENZOIL] GLICI-3- (3-HALO-5-HALO-2-HYDROXYPHENYL) COMPOUND ) -BALL ALANINE, COMPOSITION PHARMACEUTICAL AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT. | |
ECSP034732A (en) | DERIVATIVE OF PHENETHANOLAMINE FOR THE TREATMENT OF RESPIRATORY DISEASES | |
PA8547701A1 (en) | NUCLEOSIDS 4 SUBSTITUTED. | |
BR0111263A (en) | 2-Aminocarbonyl-9h-purine derivatives | |
DE60330910D1 (en) | COMPOUNDS WITH SELECTIVER INHIBITING EFFECT FOR GSK3 | |
AR032877A1 (en) | INHIBITORS FOR RENT C (1-6) -4-AMINO-AZEPAN-3-ONICOS OF PROTEASES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, USEFUL INTERMEDIARIES IN THE PREPARATION OF SUCH COMPOUNDS, PROCEDURE FOR THE SYNTHESIS OF SUCH INHIBITORS, AND USE OF DICHES INHIBITORS THE MANUFACTURE OF MEDICINES | |
AR026173A1 (en) | INHIBITORS OF NEURAMINIDASES. | |
ES2058527T3 (en) | CONDENSED DERIVATIVES OF PIRIMIDINE PROCEDURE AND INTERMEDIATE COMPOUNDS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
AR009052A1 (en) | THENOPYRIMIDINES, A PROCEDURE FOR THEIR PREPARATION, USE OF THE SAME TO PREPARE A MEDICINAL PRODUCT, PHARMACEUTICAL PREPARATIONS THAT CONSTITUTE THEM AND A PROCEDURE TO OBTAIN THESE PHARMACEUTICAL PREPARATIONS | |
BRPI0406717A (en) | Compound, pharmaceutical composition comprising the same, method of treating a disease in a mammal, use of the compound and process for its production | |
BRPI0417458A (en) | dpp-iv inhibitor compounds, pharmaceutically acceptable salts and prodrugs thereof, their preparation processes, pharmaceutical composition comprising them and use of said compounds in the manufacture of medicaments | |
AR035792A1 (en) | COMPOUNDS OF N- (4-QUINAZOLINIL) -N- (1H-INDAZOL-5-IL) AMINA, INHIBITOR OF RHO-KINASE, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND METHOD TO PREPARE IT | |
AR029403A1 (en) | N-SUBSTITUTED DERIVATIVES OF CARBAMOILOXIALQUIL-AZOLIO, A PROCESS FOR ITS MANUFACTURE, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF A MEDICINAL PRODUCT | |
BR9908545A (en) | Piperidine derivative, process for preparing it, compound, process for preparing it, and pharmaceutical composition | |
BR0113234A (en) | Polymorphs of an epothilone analog | |
UY26872A1 (en) | DERIVATIVES OF THE 4- PIRIDINE PHENYL | |
AR008377A1 (en) | A COMPOUND DERIVED FROM 3-AROYLBENCIL-PIRIDAZINONE, A PARTICULAR PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY OR AUTOIMMUNE DISEASES CONTAINING SUCH A COMPOUND | |
ECSP034744A (en) | N-REPLACED N-REPLACED NMDA / NR2B ANTAGONISTS | |
ATE406893T1 (en) | PHARMACEUTICAL COMPOSITION (KIT) CONTAINING DIHYDROPYRIDINONE COMPOUNDS AND A COMPOUND HAVING IMMUNOMODULATORY (OR ANTI-INFLAMMATORY) ACTION AND USE THEREOF | |
ES2158778B1 (en) | PAROXETINE SALT COMPOUNDS, THEIR PREPARATION AND USE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
AR003440A1 (en) | NEW AMINO ACID DERIVATIVES, PHARMACEUTICAL FORMULATION CONTAINING THEM, USE OF SUCH DERIVATIVES TO PREPARE MEDICINES AND PROCEDURE FOR THE PREPARATION OF SUCH DERIVATIVES. | |
BR0214243A (en) | Sulfonamide derivative Process for the preparation of a sulfonamide derivative and its physiologically acceptable salts, pharmaceutical composition and use of a sulfonamide derivative | |
ATE383339T1 (en) | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | |
UY27700A1 (en) | OXO COMPOUNDS - AZABYCLES. | |
AR004961A1 (en) | (R) - (-) - 2- {N- [4- (1,1-DIOXIDO-3- OXO-2,3-DIHIDRO-BENZISOTIAZOLE-2-IL) -BUTYL] -AMINOMETIL CRYSTALLINE V MODIFICATION ) CHROMAN, A PROCEDURE FOR ITS PREPARATION, MEDICINES CONTAINING IT, THE USE OF SUCH CHLORHYDRATE FOR THE PREPARATION OF MEDICINES, A COMPOSITION FOR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |